IRD Opus Genetics, Inc.
Company Analysis
Latest News
🔴 Opus Genetics is trading 5% down today amid broad selloff; no direct catalyst established
Opus Genetics is trading 5.35% down at $3.90 on October 22, 2026, with broad market pressure a plausible backdrop; available reporting does not establish a...
Opus Genetics Secures FDA Clearance to Test Childhood Blindness Therapy
Opus Genetics announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for OPGx-RDH12, an...
IRD Announces Departure of Chief Scientific and Development Officer
Opus Genetics, Inc. (IRD) disclosed that Dr. Ashwath Jayagopal will transition from his role as the company's Chief Scientific and Development Officer. The...
🟢 Opus Genetics is trading 5.6% up today amid broader biotech gains
Opus Genetics is trading 5.6% higher at $4.04 on October 20, alongside broader biotech-sector gains; no clear company-specific news was found to explain the...
🔴 Opus Genetics is trading 5% down today despite positive clinical findings
Opus Genetics is trading 5.06% lower at $3.85, despite positive clinical findings across its OPGx-BEST1 and OPGx-LCA5 programs. - OPGx-BEST1 showed improved...
🟢 Opus Genetics is trading 5.7% up in pre-market after gene-therapy findings showed improved retinal sensitivity
Opus Genetics is trading at $4.28, up 5.68%, in pre-market after reporting positive findings from its OPGx-BEST1 and OPGx-LCA5 programs. - Retinal sensitivity...
Opus Genetics Jumps 13% on Early Gene Therapy Wins, but Can a 28-Person Company Turn Tiny Trials Into Real Revenue?
Shares of Opus Genetics (IRD) surged 12.8% to $4.57 after the company reported its first meaningful clinical results from two gene therapy programs aimed at...
🟢 Opus Genetics is trading 13% up in after-hours trading after interim retinal gene therapy findings
Opus Genetics is trading 12.84% up at $4.57 in after-hours trading after reporting clinical findings from its OPGx-BEST1 and OPGx-LCA5 programs at Retina in...
🟢 Opus Genetics is trading 5% up in after-hours trading after positive gene therapy findings
Opus Genetics is trading at $4.26, up +5.19%, amid positive clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs. - At Retina in Rio...
Opus Genetics Presents Positive Clinical Data for OPGx-BEST1 and OPGx-LCA5 Programs
Opus Genetics announced positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference. The results...
🟢 Opus Genetics is trading 6.8% up in pre-market; Retina in Rio data may explain move
Opus Genetics is trading 6.83% up in pre-market at $4.38, versus October 14 close of $4.10; conference data may be a catalyst, but attribution is...
Opus Genetics to Reveal Full OPGx-BEST1 Data at Retina in Rio
Opus Genetics will present the complete clinical dataset from Cohort 1 of its Phase 1/2 trial of OPGx-BEST1 gene therapy at the Retina in Rio conference on...
🟢 Opus Genetics is trading 6.13% up in pre-market — no clear catalyst identified
Opus Genetics is trading 6.13% higher in pre-market at $4.50 on October 14, 2026, with no clear cause established by available reporting. - The company is...
🟢 Opus Genetics is trading 8.3% up in after-hours trading with no clear new catalyst
Opus Genetics is trading at $4.59, up 8.25%, in after-hours trading; available evidence does not establish a cause for the gain. - The company announced a...
🔴 Opus Genetics is trading 5% down today with biotech weakness a possible backdrop
Opus Genetics is trading at $4.41, down 5.06%, with biotech-sector weakness a plausible backdrop. • XBI fell 2.01% during the regular session, without a clear...
🟢 Opus Genetics is trading 5.5% up
Opus Genetics is trading at $4.71, up 5.49%, with no clear company-specific announcement identified for October 9. - The latest company release found was...
🟢 Opus Genetics is trading 5% up — no clear catalyst identified
Opus Genetics is trading 5.01% higher at $4.60, with no fresh company-specific announcement or clearly reported catalyst identified for the October 7 move. -...
🔴 Opus Genetics is trading 5% down
Opus Genetics is trading 5.13% down at $4.34, with no specific catalyst identified for the October 5 decline. - A director-affiliated foundation sold 556,000...
Opus Genetics Director-Affiliated Foundation Sells $2.76 Million in Stock
The Foundation Fighting Blindness Retinal Degeneration Fund, affiliated with an Opus Genetics director, sold 556,000 shares on September 30. The transaction...
🟢 Opus Genetics is trading 5% up in pre-market; catalyst remains unclear
Opus Genetics is trading 5.1% up at $4.74 in pre-market on October 2, with the reason for the rise unclear. - The investor-relations press-release page lists...